P4, N=524, Recruiting, University of Texas Southwestern Medical Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027

P1, N=85, Recruiting, Medical University of Vienna

P2, N=80, Completed, Hasanuddin University

P=N/A, N=100, Not yet recruiting, University of Alabama at Birmingham

P2, N=156, Recruiting, Second Affiliated Hospital of Nanchang University | Not yet recruiting --> Recruiting | Trial completion date: May 2028 --> May 2027 | Trial primary completion date: Dec 2027 --> Dec 2026

Pimozide also synergizes with venetoclax to induce apoptosis in CLL cells even following IL-4/CD40L signaling. This suggests that dual targeting of lysosomal function and STAT signaling represents a promising therapeutic approach to improve venetoclax efficacy and overcome TME-mediated drug resistance in CLL.

P=N/A, N=10, Terminated, University of Southern California | N=60 --> 10 | Recruiting --> Terminated; PI left institution. No one resumed the project.

P4, N=0, Withdrawn, University of Southern California | N=30 --> 0 | Trial completion date: Dec 2026 --> Dec 2030 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2026 --> Jul 2029

This novel finding sheds light on the potential molecular mechanisms of PCZ as a therapeutic strategy for HCC. In summary, our study provides fresh insights into the utility of PCZ as a therapeutic option for HCC and elucidates its molecular mechanisms.

Among these are histone deacetylase inhibitors (HDACis), receptor tyrosine kinase inhibitors, and novel agents such as ONC201 and unesbulin that target metabolic and epigenetic pathways respectively...Despite these advances, challenges such as drug delivery across the blood-brain barrier and therapeutic resistance persist, necessitating the development of combination therapies and innovative delivery methods. Ongoing research is focused on refining these strategies and exploring additional molecular and immunological targets to improve outcomes for children with DMG.

Calculated tumor volume showed exploratory predictive value but did not reach statistical significance. Importantly, baseline structural parameters should not be interpreted as substitutes for the early biochemical and radiological response at three to six months, as these responses remain the most reliable predictors of long-term responsiveness to dopamine agonists. Rather, tumor volume may represent a preliminary pre-treatment structural risk marker that requires further prospective validation.

P=N/A, N=526, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University